Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
49
UTHR Quote, Financials, Valuation and Earnings
Last price:
$481.10
Seasonality move
:
-0.46%
Day range:
$472.48 - $481.70
52-week range:
$266.98 - $519.99
Dividend yield:
0%
P/E ratio:
18.04x
P/S ratio:
7.34x
P/B ratio:
3.11x
Volume:
218K
Avg. volume:
317.9K
1-year change:
27.69%
Market cap:
$20.5B
Revenue:
$2.9B
EPS (TTM):
$26.39
Analysts' Opinion
-
Consensus RatingUnited Therapeutics Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $531.25, United Therapeutics Corp. has an estimated upside of 11.6% from its current price of $476.05.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $423.00 representing 11.14% downside risk from its current price of $476.05.
Fair Value
-
According to the consensus of 13 analysts, United Therapeutics Corp. has 11.6% upside to fair value with a price target of $531.25 per share.
UTHR vs. S&P 500
-
Over the past 5 trading days, United Therapeutics Corp. has underperformed the S&P 500 by -0.06% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
United Therapeutics Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
United Therapeutics Corp. has grown year-over-year revenues for 20 quarters straight. In the most recent quarter United Therapeutics Corp. reported revenues of $799.5M.
Earnings Growth
-
United Therapeutics Corp. has grown year-over-year earnings for 10 quarters straight. In the most recent quarter United Therapeutics Corp. reported earnings per share of $7.16.
Enterprise value:
17.7B
EV / Invested capital:
--
Price / LTM sales:
7.34x
EV / EBIT:
11.69x
EV / Revenue:
5.67x
PEG ratio (5yr expected):
1.14x
EV / Free cash flow:
15.88x
Price / Operating cash flow:
20.56x
Enterprise value / EBITDA:
11.09x
Gross Profit (TTM):
$2.8B
Return On Assets:
16.93%
Net Income Margin (TTM):
40.65%
Return On Equity:
19.2%
Return On Invested Capital:
18.69%
Operating Margin:
48.69%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $2.2B | $2.8B | $3.1B | $748.9M | $799.5M | |
| Gross Profit | $2B | $2.5B | $2.8B | $665.8M | $698.6M | |
| Operating Income | $1.1B | $1.3B | $1.5B | $343.1M | $389.3M | |
| EBITDA | $1.2B | $1.3B | $1.6B | $362.2M | $411.2M | |
| Diluted EPS | $18.15 | $22.77 | $26.39 | $6.39 | $7.16 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.4B | $3.1B | $3.5B | $4B | $3.5B | |
| Total Assets | $5B | $5.8B | $7B | $7.1B | $7.4B | |
| Current Liabilities | $320M | $315.9M | $744.1M | $873.4M | $546.3M | |
| Total Liabilities | $1.2B | $1.2B | $1.3B | $1B | $760.9M | |
| Total Equity | $3.8B | $4.6B | $5.7B | $6.1B | $6.6B | |
| Total Debt | $800M | $800M | $800M | $400M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $945.3M | $1.1B | $1.6B | $374.5M | $562.1M | |
| Cash From Investing | -$951M | $582.5M | -$446.9M | -$114.9M | $140.9M | |
| Cash From Financing | $146.6M | -$1.3B | -$1.3B | -$61.4M | -$956M | |
| Free Cash Flow | $754.1M | $898.1M | $1.1B | $298M | $346.1M | |
UTHR
Sector
Market Cap
$20.5B
$25.8M
Price % of 52-Week High
91.55%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
5.51%
-1.67%
1-Year Price Total Return
27.69%
-21.92%
Beta (5-Year)
0.854
0.499
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$476.97
200-day SMA
Buy
Level
$393.63
Bollinger Bands (100)
Buy
Level
442.87 - 493.31
Chaikin Money Flow
Sell
Level
-49.2K
20-day SMA
Buy
Level
$474.80
Relative Strength Index (RSI14)
Sell
Level
48.44
ADX Line
Neutral
Level
Williams %R
Neutral
Level
-48.9447
50-day SMA
Sell
Level
$485.66
MACD (12, 26)
Buy
Level
37.98
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Sell
Level
-218K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (12.4073)
Buy
CA Score
(Annual)
Level (2.1364)
Buy
Beneish M-Score
(Annual)
Level (-2.3521)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-6.3954)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
Stock Forecast FAQ
In the current month, UTHR has received 8 Buy ratings 5 Hold ratings, and 0 Sell ratings. The UTHR average analyst price target in the past 3 months is $531.25.
-
Where Will United Therapeutics Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that United Therapeutics Corp. share price will rise to $531.25 per share over the next 12 months.
-
What Do Analysts Say About United Therapeutics Corp.?
Analysts are divided on their view about United Therapeutics Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that United Therapeutics Corp. is a Sell and believe this share price will drop from its current level to $423.00.
-
What Is United Therapeutics Corp.'s Price Target?
The price target for United Therapeutics Corp. over the next 1-year time period is forecast to be $531.25 according to 13 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is UTHR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for United Therapeutics Corp. is a Buy. 8 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of UTHR?
You can purchase shares of United Therapeutics Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase United Therapeutics Corp. shares.
-
What Is The United Therapeutics Corp. Share Price Today?
United Therapeutics Corp. was last trading at $481.10 per share. This represents the most recent stock quote for United Therapeutics Corp.. Yesterday, United Therapeutics Corp. closed at $476.05 per share.
-
How To Buy United Therapeutics Corp. Stock Online?
In order to purchase United Therapeutics Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get UTHR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
UTHR
Sector
P/E ratio
18.04x
23.35x
PEG ratio
1.14x
-0.01x
P/B ratio
3.11x
1.78x
Price / LTM sales
7.34x
1.55x
Growth Metrics
UTHR
Sector
Revenue growth
6.76%
3.74%
Earnings growth
12.12%
11.14%
Revenue (5-year growth)
14.71%
6.38%
Earnings forecast
$7.24
-$0.19
Profitability
UTHR
Sector
Profitability FY 2024
$2.6B
$2.6M
Return on invested capital
18.69%
-32.91%
Return on assets
16.93%
-29.56%
Return on equity
19.2%
-38.66%
Earnings Date
Last Earnings Date
Oct
29
Next Earnings Date
Feb
25
Estimated Next Earnings Date
Jan
28
Balance Sheet
UTHR
Sector
Total cash
$2.8B
$25.2M
Short term investments
$1.6B
$24.1M
Total assets
$7.4B
$72.8M
Long term debt
--
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
73
HYMC alert for Feb 19
Hycroft Mining Holding Corp. [HYMC] is up 3.81% over the past day.
Buy
57
GLBE alert for Feb 19
Global-e Online Ltd. [GLBE] is up 4.19% over the past day.
Sell
37
ACLS alert for Feb 19
Axcelis Technologies, Inc. [ACLS] is down 1.71% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
